Julia Cartwright explores groundbreaking research showing semaglutide (Ozempic/Wegovy) reduces heart failure hospitalizations by 70% in HFpEF patients—a stubborn condition affecting millions with few treatment options. The episode examines clinical trial data revealing benefits beyond weight loss, including reduced inflammation and improved heart function, marking a potential paradigm shift in cardiovascular medicine.
Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV
This content was created in partnership and with the help of Artificial Intelligence AI
This episode includes AI-generated content.
続きを読む
一部表示